SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 25, 2026Sponsor estimate | NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune Thrombocytopenia | SNYLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Nov 28, 2026Sponsor estimate | NCT07103148A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationSanofi · Yellow Fever Immunization | SNYLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 25, 2026Sponsor estimatePhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2026Sponsor estimatePhase 3NCT07103148A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationSanofi · Yellow Fever ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 1, 2026Sponsor estimate | NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal Infections | SNYLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal InfectionsActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 15, 2027Sponsor estimate | NCT04644575Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ABioverativ, a Sanofi company · Hemophilia A | SNYLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 15, 2027Sponsor estimatePhase 3NCT04644575Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ABioverativ, a Sanofi company · Hemophilia AActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 17, 2027Sponsor estimate | NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal Polyps | SNYLeadREGNCollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 17, 2027Sponsor estimatePhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.